AI assistant
Vitrolife — Share Issue/Capital Change 2012
Nov 30, 2012
2989_rns_2012-11-30_c2776c86-0f3f-4789-8fcf-5dfea79cd1d9.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Press Release November 30, 2012 Gothenburg
Vitrolife's share capital and number of shares on November 30, 2012
As per November 30, 2012, the total number of shares in Vitrolife AB (publ) amounts to 19,830,936, of which Vitrolife itself holds 0 shares. The share capital amounts to SEK 20,227,554.74.
At the beginning of the month the total number of shares in the company amounted to 19,562,769, of which Vitrolife itself held 0 shares. The share capital amounted to SEK 19,954,024.38
The increase in the number of shares by 268.167 during the month of November is due to the private placement that was directed to the previous owners of Cryo Management Ltd to partly finance the acquisition of Cryo Management Ltd. For more information regarding the private placement and the acquisition, see previous press releases on Vitrolife´s website.
November 30, 2012 VITROLIFE AB (publ) Thomas Axelsson CEO
Queries should be addressed to:
Thomas Axelsson, CEO, phone +46 31 721 80 01 Mikael Engblom, CFO, phone +46 31 721 80 14
Vitrolife is a global biotechnology/medical device Group. Vitrolife´s Fertility product area develops, produces and markets products for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes.
______________________________________________________________________________________________________________________
Vitrolife today has ca 220 employees and its products are sold in ca 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China, Japan and Hungary. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap. ___________________________________________________________________________________________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: [email protected]. Website: www.vitrolife.com
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 30, 2012 at 5:00 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.